GlassScriptPhysician profile
Kevin H Ashby
NPI 1245209907
$4,941.48
in general payments reported to CMS, 2019-2025
25 companies · $763 in 2025
The $763 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $645 · 2020: $325 · 2021: $614 · 2022: $1,088 · 2023: $774 · 2024: $732 · 2025: $763.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,269.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $698.73 | 2019-2025 | Livdelzi |
| Abbvie INC. | $457.76 | 2021-2025 | |
| Intercept Pharmaceuticals, INC. | $434.29 | 2020-2024 | Ocaliva |
| Janssen Biotech, INC. | $397.01 | 2023-2025 | Tremfya, Stelara |
| Nestle Healthcare Nutrition INC. | $274.25 | 2020-2022 | |
| Janssen Scientific Affairs, LLC | $253.30 | 2022 | |
| Phathom Pharmaceuticals, INC. | $248.85 | 2024 | Voquezna |
| Medtronic, INC. | $242.87 | 2022-2025 | Barrx, Venaseal |
| E.R. Squibb & Sons, L.L.C. | $238.61 | 2021-2023 | Zeposia |
| Allergan, INC. | $209.92 | 2019 | |
| Erbe USA INC | $178.12 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.81 | 2019-2022 | |
| Exact Sciences Corporation | $161.69 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $152.79 | 2020-2023 | |
| Madrigal Pharmaceuticals | $141.81 | 2024 | Resmetirom |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $141.42 | 2022 | |
| Aimmune Therapeutics, INC. | $124.88 | 2025 | Zenpep |
| Lilly USA, LLC | $118.45 | 2025 | |
| Apollo Endosurgery US INC | $111.08 | 2023 | Overstitch Endoscopic Suturing System |
| Takeda Pharmaceuticals U.S.A., INC. | $53.46 | 2020-2021 | |
| Genzyme Corporation | $51.89 | 2022 | |
| Glaxosmithkline, LLC. | $24.28 | 2019 | |
| Braintree Laboratories, INC. | $22.62 | 2021 | |
| Qol Medical, LLC | $21.20 | 2019 | |
| Merck Sharp & Dohme LLC | $19.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Ashby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.